

BDR Pharma launches India's first generic Midostaurin for leukemia treatment

07 December 2021 | News

Midostaurin is launched under the brand name MSTARIN



Mumbai-based BDR Pharma has announced the launch of India's first generic- Midostaurin under the brand name MSTARIN, which is indicated in rare, hard-to-treat cancers.

The drug is approved for use in combination with standard Daunorubicin & Cytarabine induction and high-dose Cytarabine consolidation chemotherapy, and for patients in complete response followed by Midostaurin single-agent maintenance therapy for adults with newly diagnosed Acute Myeloid Leukemia (AML) who are FLT3 mutation-positive.

The drug will have a strength of 25 mg, in the form of capsules.